Approximately one third of patients with non-small cell lung cancer have unresectable stage IIIA or stage IIIB disease; combined cytotoxic chemotherapy and radiation therapy delivered concurrently has been established as the standard treatment for such patients. Despite many clinical trials that tested several different radiochemotherapy combinations, it seems that a plateau of efficiencies at the acceptable risk of complications has been reached. Clinical studies indicate that the improved efficacy of radiochemotherapy is associated with the radiosensitizing effects of chemotherapy. Improvement of outcomes of this combined modality by developing novel radiosensitizers is a viable therapeutic strategy. In addition to causing cell death, ionizing radiation also induces a many-faceted signaling response, which activates numerous prosurvival pathways that lead to enhanced proliferation in the endothelial cells and increased vascularization in tumors. Radiation at doses used in the clinic activates cytoplasmic phospholipase A2, leading to increased production of arachidonic acid and lysophosphatidylcholine. The former is the initial step in the generation of eicosanoids, while the later is the initial step in the formation of lysophosphatidic acid, leading to the activation of inflammatory pathways. The echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) is member of the insulin superfamily of receptor tyrosine kinases. The EML4-ALK fusion gene appears unique to lung cancer and signals through extracellular signal regulated kinase and phosphoinositide 3-kinase. Heat shock protein 90 (Hsp90) is often overexpressed and present in an activated multichaperone complex in cancer cells, and it is now regarded as essential for malignant transformation and progression. In this review we focus on radiosensitizing strategies involving the targeting of membrane phospholipids, EML4-ALK, and Hsp90 with specific inhibitors and briefly discuss the combination of radiation with antivascular agents.
I t is estimated that in 2013, lung cancer will cause about 30% of all cancer deaths among men and 27% of all cancer deaths among women in the United States (a total of 163,890 deaths), which is more than the combined number of deaths from the next 3 most common causes of cancer deaths, namely, colon, breast, and prostate cancers. 1 Worldwide, in 2008, lung cancer was the leading cause of cancer deaths in males and the second leading cause of cancer deaths in females, about 1,400,000, or 18% of all cancer deaths. Five-year survival rates for lung cancer patients range from 6% to 18%. The 5-year survival rate has changed only very little during the last 2 decades, with progress lagging significantly behind other common cancers. Conventionally, lung cancer is divided into small and non-small cell subtypes, the latter accounting for around 85% of cases. This review will focus on non-small cell lung cancer (NSCLC). The combination of standard chemotherapy with radiotherapy therapy (RT), chemoradiotherapy (CRT), is used routinely for stage III NSCLC patients. 2Y4,13 Concurrent CRT has been shown to be more effective than consequent CRT. 5 Unfortunately, the survival benefit of concurrent regimens above sequential regimes of CRT carries the risk of additional toxicity. 5 Two recent comprehensive meta-analyses of CRT clinical trials have shown that local disease control by RT is important and contributes to improved survival. 3, 5 These results indicate that the success of CRT is a reflection of the radiosensitizing effect of chemotherapy due to its action on tumor biological factors that can affect the response to RT. Thus, improvement of the efficacy of RT would also lead to the improvement of CRT outcomes. One strategy toward achieving this goal is the development of novel radiosensitizers, which is the focus of this review.
Three main aspects of tumor biology that are well known to affect RT outcome are the extent of hypoxia, the ability of the surviving tumor cells to repopulate within treatment time, and the intrinsic radioresistance of tumor cells. 6 Convincing evidence for a role for each of these radiobiological factors in RT has accumulated from many clinical studies at all treatment sites. 7 Evidence has also been accumulating that tumor vasculature and stromal cells also play a crucial role in the response to cancer therapy, including RT. 8, 9 RADIOTHERAPY Currently, definitive radiotherapy is mainly used for stage I inoperable NSCLC, for which the advancement of stereotactic techniques has led to impressive outcomes. 10Y12 The combination of chemotherapy with RT and CRT is used routinely for stage III NSCLC patients. 2Y4,13 Concurrent CRT has been shown to be more effective than consequent CRT. Unfortunately, the survival benefit of concurrent regimens above sequential regimens of CRT carries the risk of additional toxicity. 5 Two recent comprehensive meta-analyses have shown that local disease control by RT is important and contributes to improved survival. This important outcome gives a strong impetus to the continued improvement of radiation treatments. The outcome of RT is dependent on accurate delineation of the tumor area and all involved lymph nodes. 7 Inadequate treatment planning strategies will increase the chance of local recurrences or result in a higher chance of normal tissue damage, or both. Innovations, such as the introduction of three-dimensional conformal planning, the use of multileaf collimators, four-dimensional planning computed tomographic scans, intensity-modulated radiation therapy (IMRT), and image-guided radiation therapy (IGRT) techniques have dramatically improved targeting of the tumor volume. 14, 15 These new radiation delivery techniques have allowed for significant dose escalation, without concurrent increases in normal tissue toxicity. 14, 15 The use of intensity-modulated radiation therapy can achieve a dose escalation of 20% to 35% compared with three-dimensional conformal radiotherapy by more conformal dose distributions and steeper dose fall off. Clinical trials determining the effect of higher doses achieved with the advanced radiation techniques are being conducted currently. Although the concurrent CRT schedule has been favored with an absolute survival benefit, there is no difference in progression-free survival (PFS). The concurrent regimen primarily improved local regional control but did not affect the rate of distant progression. The increased PFS achieved by CRT is probably the result of the radiosensitizing effect of chemotherapy, through the action of chemotherapeutic agents on the tumor that can effect its response to RT.
RADIATION-INDUCED SIGNALING
During the last two decades, it has been shown that ionizing radiation at doses used in the clinic, in addition to inducing DNA damage in the nucleus, also triggers the activation of a large network of intracellular signaling events. 16 These include the transient activation of central regulators of prosurvival response pathways and the induction of inflammation. 17 Many of the inflammatory cascades elicited by radiation are injurious to normal tissues, but they confer a survival advantage to tumor cells. Thus, specific targeting of downstream components of the radiation-inducible inflammatory signaling response offers the possibility of simultaneously abrogating radioresistance within tumor cells and blocking deleterious inflammatory responses of normal tissues to RT. 18 In general, intrinsic tumor radiosensitivity has been thought to mainly reflect the balance between radiation-induced DNA damage and its repair. Recent results indicate that the cascade of radiation-induced cytoplasmic signaling events described above also plays a salient role in tumor radiosensitivity. 19 The cellular signaling triggered by clinical doses of ionizing radiation occurs at two discrete sites: the nucleus and the cytoplasm. In the nucleus, a DNA damage response is elicited, which coordinates DNA repair, cell cycle checkpoints, and cell death pathways. 20 The structure of this response involves molecules that sense the DNA damage, which elicits the participation of several mediators, such as ATM, which, in turn, recruit an army of proteins that are key players in several pivotal cellular processes. Thus, the DNA damage response regulates physiological processes that involve multiple layers of decisions, including the determination to undergo apoptosis or enter terminal differentiation through senescence, the activation of heightened immune surveillance, as well as DNA repair itself.
In the cytoplasm, the radiation-generated ionizing events in water are amplified in the mitochondria in a Ca 2+ -dependent manner, leading to the generation of large amounts of reactive oxygen species and reactive nitrogen species. 21 The resulting redox imbalance leads to the inhibition of protein tyrosine phosphatase (PTPase) activities. 22 The relative activity of a PTPase is approximately one order of magnitude higher than that of the substrate (kinase) it dephosphorylates. 23 PTPase activity is sensitive to oxidation or nitrosylation of a key cysteine residue in its active site, or both, and thus, any agent that generates reactive oxygen species or reactive nitrogen species has the potential to lead to decreased PTPase activity and, hence, increased tyrosine phosphorylation of multiple proteins. 24 As a net result of the decreased PTPase activity, there is increased tyrosine phosphorylation, resulting in the activation of receptor and non-receptor tyrosine kinases and the activation of downstream signal transduction pathways.
In addition, radiation activates acidic sphingomyelinase and increases the production of ceramide. Radiation-induced ceramide has been shown to promote membrane-associated receptor activation by facilitating the clustering of receptors within lipid rafts. 25, 26 Radiation also induces the eicosonoid inflammatory pathway by inducing increased activity of cytoplasmic phospholipase A2 (cPLA 2 ), resulting in increased levels of arachidonic acid that is metabolized through cyclooxygenase-2 (COX-2), which is also induced by radiation, into various forms of prostaglandins. 27 
EICOSONOIDS
Inflammation is now recognized as a critical component for tumor progression and one of the recently added hallmarks of cancer. 28, 29 Epidemiological and genetic studies support the link between chronic inflammation and tumor progression. 30 Eicosanoidgenerating enzymes, such as COX-2 and 5-lipoxygenase, are overexpressed in several cancers including breast, lung, and pancreas. 31 Eicosanoids, including prostaglandins and leukotrienes, are generated by local cell type-specific arachidonic acid metabolism and can be potent mediators of inflammation. The enzyme families COX and lipoxygenase are responsible for the metabolism of arachidonic acid, leading to the production of prostaglandins and leukotrienes, respectively. Both of these pathways have been implicated in cancer progression. 31, 32 There are two types of COX activities in cells, COX-1 and COX-2. COX-1 is constitutively expressed, whereas COX-2 is inducible. Several different cancers are found to overexpress COX-2, including lung cancer. 33 Interestingly, overexpression of COX-2 alone causes tumorigenesis in transgenic mouse models. 34 Ionizing radiation activates cPLA 2 , triggering the release of arachidonic acid from membrane phospholipids and subsequent production of eicosanoids through the COX pathways. COX-2 is also induced by radiation in various cell culture models, including NSCLC. 35, 36 In many tissues, radiation exposure leads to increased eicosanoid production. Within hours after irradiation, increased levels of prostaglandins (PG)E1, PGE2, PGF2, and PGI2 are detectable in most tissues, and the increased levels of eicosanoid may persist for several days or weeks. 27 Tumor models of lung, brain, breast, and sarcomas treated with the pan-COX inhibitor, indomethacin, before irradiation improved the therapeutic index, because the effects of radiation on tumors was enhanced, whereas those on normal tissue effects were not. 37 In mouse fibrosarcoma, daily treatment with indomethacin before radiotherapy improved the responses in both single and fractionated dose regimens. Indomethacin treatment was associated with prolonged delays in tumor growth, an increased cure rate, and increased time to recurrence, with no significant change in normal tissue response. Indomethacin inhibits both COX-1 and COX-2. 27 Several studies involving animal tumor models also demonstrated radiation sensitizing effects of selective COX-2 inhibition. No substantial increase in radiation-induced normal tissue damage was seen, suggesting that selective COX-2 inhibition was associated with a true therapeutic gain for radiotherapy. 37 In several studies, the antiangiogenic actions of COX-2 inhibitors have been implicated in the increased radioresponse. 37 The expression of COX-2 has been documented in up to one third of lung-atypical adenomatous hyperplasia and carcinoma in situ and is also overexpressed in 70% to 90% of NSCLCs, especially in adenocarcinomas. 38, 39 Increased COX-2 messenger RNA levels indicate a worse overall survival rate and a more aggressive disease in NSCLC. 40, 41 A recent metaanalysis of 16 studies found that COX-2 overexpression seems to have no significant impact on survival of NSCLC patients. 42 The availability of specific COX-2 inhibitors, such as celecoxib, has led to clinical trials involving NSCLC patients. Several such clinical trials were reviewed recently, including the effect of celecoxib on first-line treatment, second-line treatment, and in combination with epidermal growth factor receptor (EGFR) inhibitors. 43 All 13 studies were phase I/II; increased progression-free survival and overall survival were reported in one study, whereas in a second-line study, using a doublet chemotherapy protocol, the patients receiving the specific COX-2 inhibitor, celecoxib, fared worse. Two large, randomized, phase III trials studied the effect of celecoxib on salvage chemotherapy in stage IIIb/IV NSCLC; both studies failed to demonstrate a survival benefit of the addition of celecoxib to palliative chemotherapy. 44, 45 Two clinical trials combining chemotherapy, radiation, and celecoxib have also been published recently. 46, 47 Although one study was too small and one closed because it did not meet its response rate goals, both studies observed that in unselected patients, the addition of celecoxib to concurrent chemoradiotherapy with inoperable stage IIIA/B NSCLC does not improve survival. Several ongoing trials were halted because of the cardiovascular side effects of celecoxib.
CYTOSOLIC PHOSPHOLIPASE A2
The enzymatic action of cPLA 2 on membrane releases both arachidonic acid and lysophospholipids (LPC). Whereas the arachidonic acid is metabolized by COX-1 and COX-2 to generate eicosanoids, LPC is metabolized to lysophosphatidic acid (LPA). We have been studying the cPLA 2 -autotaxin (ATX) axis to improve the efficacy of radiotherapy in lung cancer and glioblastoma. 48Y51 PLA 2 are biologically active enzymes that catalyze the hydrolysis of membrane phospholipids at the sn-2 position to release lipid second messengers that play a vital role in cancer. 52 Three major classes of PLA 2, namely secretory PLA 2 , Ca 2+ independent PLA 2 , and cytoplasmic PLA 2 , have been identified based on their biological roles in the cell. Ionizing radiation triggers the activation of cPLA 2 , which cleaves phosphatidylcholine to yield LPC, metabolism of which activates Akt and extracellular signal regulated kinase (ERK)1/2 51 (Fig. 1 ). Inhibition of cPLA 2 prevented radiation-induced activation of ERK1/2 and decreased clonogenic survival of irradiated vascular endothelial cells. 49 cPLA 2 has been shown to promote the growth and survival of endothelial cells after irradiation, which led to growth and survival of vascular endothelium, improved migration, and tumor formation. 49, 50, 53 Activation of cPLA 2 by irradiation leads to increased vasculature and enhanced tumorogenesis and invasion leading to radioresistance of the tumor and diminishing the efficacy of the radiotherapy of the tumor models. 55 Radiation-induced cPLA 2 dependent signaling has been identified to regulate cell viability. cPLA 2 has been implicated in eliciting inflammatory response among the other cellular responses. Increased phospholipase signaling has been implicated to various cancers and disease pathogenesis. 55Y57 In normal tissue, vasculature pericytes are quiescent and provide important mechanical and physiological support. During tumor angiogenesis, pericytes are activated and rapidly proliferate and differentiate, and these detached pericytes aid endothelial cells in form new blood vessels. 58 cPLA 2 knockout (cPLA 2 -KO) mice injected with Lewis lung carcinoma (LLC) cells formed smaller tumors than wild-type (WT) mice. The LLC tumors that formed in the cPLA 2 -KO mice later regressed. Interestingly, tumors in cPLA 2 -KO mice had dramatically decreased pericytes. Because pericytes regulate vascular integrity and maintenance, 58, 59 regression of LLC tumors could be the result of the lack of pericytes in cPLA 2 -KO mice. 50 Orthotopic mouse lung tumors (CMT167 and LLC) form a primary tumor, followed by metastasis, which was reduced in cPLA 2 -KO mice. WT mice transplanted with cPLA 2 -KO bone marrow showed a better survival advantage compared with mice receiving the bone marrow of WT mice. 60 Inhibition of cPLA 2 using a chemical inhibitor, CDIBS, delayed heterotopic LLC tumor growth in mice. 50 In WT mice, FIGURE 1. Phospholipase A signaling in response to ionizing radiation. Ionizing radiation activates cytosolic phospholipase A2 (cPLA 2 ), which cleaves phosphatidylcholine (PC) to yield lysophospholipids (LPC). LPC can phosphorylate Akt and extracellular signal-regulated kinase 1/2 (ERK1/2). This activation leads to increased vasculature and enhanced tumorogenesis and invasion leading to radioresistance of the tumor. LPC is a secondary messenger to many signaling pathways that stimulate endothelial survival and proliferation by regulating the cytokine synthesis, endothelial growth factor expression, and chemotaxis. Autotaxin (ATX) that possess the lysophospholipase D (LysoPLD) activity catalyzes the reaction by cleaving the head group of LPC to form lysophosphatidic acid (LPA). LPA can then bind to LPA receptors (LPA 1-3 ). LPA 1-3 belongs to the endothelial differentiation gene family (EGD). LPA 1 is highly expressed in the nervous system and is required for development of the brain. LPA 2 is highly expressed in immune system organs, such as the thymus and spleen. LPA 3 is highly expressed in reproductive organs, such as the testis and uterus, and is linked with ovarian cancers.
the studies looking at the tumor microenvironment revealed that cPLA 2 recruit macrophages and stimulate the production of inflammatory cytokine interleukin-6, leading to tumor formation. Histological analysis of the LLC tumors grown in cPLA 2 -KO mice had fewer blood vessels in their tumors. 54 The combination of irradiation with inhibition of cPLA 2 in preclinical lung cancer tumor models has been shown to suppress growth and to reduce blood flow. 61 
AUTOTAXIN
LPC is a second messenger in many lipid signaling pathways that stimulate endothelial cell survival and proliferation by regulating cytokine synthesis, endothelial growth factor expression, and chemotaxis. 62 ATX converts extracellular LPC to LPA through its lysophospholipase D activity. ATX belongs to the ectonucleotide pyrophosphate/phosphodiesterase (ENPP) family and is encoded by the ENPP2 gene. 63 The cellular effects of LPA are mediated through the six distinct G-proteinYcoupled receptors (GPCRs). 64 Recent studies show that ATX is not only a lysoPLD enzyme, but is also a lipid carrier protein that efficiently transports LPA to respective cognate GPCRs. 65 Receptor expression is cell type specific, and this allows unique cellular responses to LPA, depending on the type of GPCR it is binding. GPCRs mediate cellular effects, such as migration and proliferation in cancer. 66 ATX was originally identified as a tumor motility protein and is overexpressed in various cancers, including NSCLC, 63 and known to contribute to the tumor invasiveness. 67 There is direct evidence in transgenic mice indicating that ATX and LPA are involved in invasiveness and metastasis of breast cancer. Increased expression of ATX and its receptors, LPA 1 , LPA 2 , and LPA 3 , in mammary epithelium of transgenic mice induced estrogen-positive mammary cancer. 68 ATX has been shown to stimulate angiogenesis either by enhancing the expression of vascular endothelial growth factor (VEGF) 69 or by stimulating motility 70 in endothelial cells. It has been shown that in Hodgkin lymphoma, cell motility is dependent on the ATX expression and expression of LPA receptors. 71 Brp-LPA, a pan-antagonist of LPA 1-4 receptors and inhibitor of the lysoPLD activity of ATX, was shown to inhibit cell migration and cell invasion of lung cancer cells 72 and glioblastoma cells. 48 In a three-dimensional lung cancer xenograft model, Brp-LPA inhibited tumor growth and reduced tumor vascularization. 72 Inhibition of ATX and LPA receptors by Brp-LPA diminished the radiation-induced activation of prosurvival kinase Akt. Brp-LPA treatment enhanced radiation-induced endothelial cell death, disrupted endothelial cell biological functions, and reduced glioma cell viability and migration. 48 The specific ATX inhibitor, PF8380, reduces the LPA levels in the tumor microenvironment and blocks LPA signaling. 51 
ANAPLASTIC LYMPHOMA KINASE
The echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) fusion oncogene represents one of the newest molecular targets in NSCLC. EML4-ALK was first identified in 2007 by Soda and colleagues 73 by screening a complementary DNA library derived from the tumors of Japanese male patients with adenocarcinoma of the lung. 73 Chromosomal aberrations involving ALK have been identified in several other cancers, including anaplastic large-cell lymphomas, inflammatory myofibroblastic tumors, and neuroblastomas. 74 In cases of ALK translocations, including EML4-ALK, the fusion partner has been shown to mediate ligand-independent dimerization of ALK, resulting in constitutive kinase activity. In cell culture systems, EML4-ALK possesses potent oncogenic activity. In transgenic mouse models, lung-specific expression of EML4-ALK leads to the development of numerous lung adenocarcinomas. 75 The growth of cell lines and tumors harboring the EML4-ALK translocation is inhibited by small molecule inhibitors targeting ALK. 75, 76 These results support the concept that ALK-driven lung cancers are addicted to the kinase activity of the fusion EML4-ALK oncogene. 77 ALK is thought to play a role during the development and function of the nervous system, and it is not expressed in most, if any, adult tissues, including the lung. ALK KO mice are completely viable without any obvious alterations. 74 The ligands involved in the activation of ALK are yet to be identified. The key downstream effectors of ALK are better understood than the putative upstream activators (Fig. 2) . A number of EML4-ALK variants have been identified in NSCLCs, all of which appear to confer gain-of-function properties. 78 Similar to EGFR mutations, EML4-ALK fusions result in constitutive tyrosine kinase activity, dependence of the cancer cell on the activated downstream mitogenic pathways, and exquisite sensitivity to ALK inhibition and, thus, are another example of oncogene addiction. 79 Lung cancers harboring ALK rearrangements represent a unique subpopulation of lung cancer patients. The frequency of ALK rearrangements ranges from 3% to 7% in unselected NSCLC patients. 80, 81 Similar to EGFR mutations, the frequency of this genetic alteration is higher in NSCLC patients with adenocarcinomas and in patients who have never smoked or are light cigarette smokers. ALK rearrangements tend to be mutually exclusive with EGFR and KRAS mutations and to have a lower frequency of p53 mutations. 76, 81 In these tumors, ALK is the sole determinant of critical growth pathways, resulting in the activation of downstream canonical phosphoinositide 3-kinase (PI3K)/AKT, as well as MAPK/ERK pathways. Given the significant fraction of ALK-related cancers, this population could represent more than 10,000 new cases in the United States and more than 70,000 worldwide. The initial studies reporting the discovery of EML4-ALK raised the possibility that inhibiting the kinase activity of ALK may be an effective clinical therapy. 73, 75 Treatment of EML4-ALK NSCLC cell lines with ALK-kinase inhibitors, which were developed for non-Hodgkin lymphoma-associated NPManaplastic lymphoma kinase, led to the down-regulation of critical survival signaling pathways and apoptosis, 76, 82, 83 similar to the effect of EGFR inhibitors in EGFR mutant NSCLC. 84 In the xenograft models generated from EML4-ALK NSCLC cell lines, ALK inhibitors regressed tumors effectively. 75, 76 Presently, only one agent targeting ALK, PF-02341066 (crizonitib), which was initially designed as an inhibitor of metastasis, is in clinical use, although others have been examined in preclinical model systems. 75, 76, 85, 86 The first phase I study of crizonitib demonstrated a remarkable 53% response rate and a disease control rate of 79%. 87, 88 The clinical benefit of crizotinib therapy is limited by the development of acquired resistance, as is the case with EGFR tyrosine kinase inhibitors (TKI). At least eight different point mutations conferring resistance to ALK inhibitors have already been described in detail, and most of them have been shown to result in crossresistance to other ALK inhibitors. 89, 90 Multiple distinct mutations in the ALK kinase domain can abrogate the inhibitory capacity of crizotinib, in sharp contrast to EGFR-activating mutations, where the gate keeping T790M mutation essentially represents the sole resistance mutation. 91 Bypass signaling, including the KIT and EGFR pathways, has been identified as potential resistance mechanisms. 92Y94 From a therapeutic standpoint, the wide array of resistance alterations will make it challenging to develop strategies to overcome ALK inhibitor resistance. 95 The potential radiosensitizing effect of ALK inhibitors has been reported in two recent studies. Sun and coworkers 96 showed that crizonitib radiosensitized NSCLC cells and xenografts expressing EML4-ALK. Another study reported the lack of radiosensitization under similar experimental conditions. 97
HEAT SHOCK PROTEIN 90
Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that regulates the late-stage maturation, activation, and stability of a diverse range of client proteins (defined as proteins with demonstrated binding to Hsp90). There are more than 200 identified clients, many of which are involved in signal transduction and other key pathways that are especially important in malignancy. 98 Although it is highly expressed in normal cells, where it helps to maintain protein homeostasis, Hsp90 is exploited by cancer cells for at least 2 purposes: (i) to support the activated or metastable forms of oncoproteins, including many kinases and transcription factors; and (ii) to buffer cellular stresses induced by the malignant lifestyle. 99, 100 The classical driver-mutation view of oncogenesis and cancer progression has inspired the design of novel therapeutics targeting driver oncogenes as susceptible nodes in the complex signaling networks regulating the hallmark traits of malignancy. 29, 101 However, the addiction of individual cancers to specific oncogenes is only a single component of molecularly multifaceted aspects of cancer. The maintenance of the conditions required to sustain tumor growth requires regulation of the microenvironment and also significantly alters intracellular homeostasis to deal with the metabolic burden of rapid clonal expansion in low nutrient conditions resulting from deregulated cellular proliferation. 29, 102 Meeting these demands may occur by the up-regulation of a repertoire of stress responses found in normal and cancer cells. Cancer cells are thought to be particularly dependent on the upregulation of such non-oncogene pathways for survival. 99, 100 Recently, it has also been established that the genomic instability associated with cancer cells results in aneuploidy, gene copy number variation, chromosomal translocations, missense mutations, and increased cellular concentrations of proteins with suboptimal stability, leading to proteotoxic stress. Thus, an increased requirement for proteostasis is now an additional hallmark feature of cancer. 102 Hsp90 is at the hub of oncogenic proteostasis, which entails the functional and structural stabilization of a host of known oncoproteins. 103, 104 Hsp90 is often overexpressed 105 and present in an activated multichaperone complex in cancer cells, 106 and it is now regarded as essential for malignant transformation and progression. 100 It has been demonstrated that a number of mutated oncoproteins, including, for example, BRAF and EGFR, are much more dependent on Hsp90 than the corresponding WT proteins. 100 The combination of the observations outlined previously generate a strong case for targeting the Hsp90 molecular chaperone for cancer treatment, because cancer cells are expected to be more sensitive to Hsp90 inhibitors than normal cells.
Since the first study demonstrating that the chaperoning of an oncoprotein Hsp90 was required for transformation by using a targeted inhibitor of Hsp90, 107 there has been an explosion in the development of novel inhibitors of Hsp90 and efforts to bring them to the clinic for various cancers. 108, 109 Two excellent perspectives on future directions were published recently. 110, 111 The EMK4-ALKT fusion oncoprotein was shown to be associated with Hsp90, and the new Hsp90 inhibitor, IPI-504, was shown to lower EMK4-ATK levels in cells in culture and xenografts, leading to growth inhibition. 112 Significantly, cells that were selected for AKL-kinase inhibitor resistance, retained their sensitivity to IPI-504. Patients with advanced NSCLC, prior treatment with EGFR TKIs, and tumor tissue available for molecular genotyping were enrolled in a prospective, nonrandomized, multicenter, phase II study of IPI-504 monotherapy. Best outcomes for over all response rate were the patients carrying ALK gene rearrangements. 113 In one study, ganetespib another Hsp90 inhibitor monotherapy demonstrated a manageable side effect profile, as well as clinical activity in heavily pretreated patients with advanced NSCLC, particularly in patients with tumors harboring ALK gene rearrangement. 114 A panel of lung cancer cell lines harboring a diverse spectrum of KRAS mutations was treated with ganetespib, leading to potent cytotoxicity with concomitant destabilization of KRAS signaling effectors. Combinations of low-dose ganetespib with MEK or PI3K/mTOR inhibitors resulted in superior cytotoxic activity to single agents alone in a subset of mutant KRAS cells. 115 Ganetespib induced loss of EML4-ALK expression and depletion of multiple oncogenic signaling proteins in ALK-driven NSCLC cells and xenografts. 116 Studies with NVP-AUY922, a novel potent resorcinylic isoxazole amide inhibitor of Hsp90 have been reported; recently. In one study, the effects on NSCLC cells lines were reported; the later study, also included xenograft models. 117, 118 Both studies reported excellent results, and the establishment of clinical trials is in progress.
Pretreatment of cancer cells with Hsp90 inhibitors leads to the radiosensitization of cancer cells of various types, including NSCLC. Studies were performed with Geldanamycin (GM) and two derivatives of GM, 17AAG and 17DMAG. These specific inhibitors of Hsp90 are potent radiosensitizers, achieving radiation enhancement ratios ranging from 2.3 to 2.7. Interestingly, normal fibroblasts were not radiosensitized under similar experimental conditions. 119 Recently, inhibitors of Hsp90 with improved bioavailability and lower toxicity have become available, including a series of pyrazole resorcinol compounds that have proven to be stronger inhibitors of Hsp90 (NVP-AUY922). 120 Treatment of cancer cells, including NSCLC, with NVP-AUY922 leads to radiosensitization under normoxic and hypoxic condition. 121, 122 The radiosensitization was accompanied by effects on DNA repair, cell cycle progression, 123 and abrogation of homologous recombination, leading to mitotic entry with unresolved DNA damage. 124 
COMBINATION OF CRT WITH AGENTS TARGETING ANGIOGENESIS
Several therapies targeting angiogenesis are currently in development for NSCLC. Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. Completed phase III trials evaluating bevacizumab plus chemotherapy have shown prolonged progression-free survival; however, not all trials showed significant improvement in overall survival. 125 Vascular targeting agents are considered to have a low toxicity level, as they should only affect the angiogenic vessels. However, toxicities have been observed in the clinical setting when angiostatic drugs were combined with cytotoxic therapies. 125 Phase III trials of the TKIs targeting VEGFR, vandetanib and sorafenib, and the vascular disrupting agent, ASA404, also failed to improve survival compared with chemotherapy alone. Other phase III clinical trials are ongoing, involving several new angiostatic agents that have shown promising phase I/II results, including new antibodies and multiple kinase inhibitors. 126 Two updates on new single and multitargeted agents have been published recently. 126, 127 In considering the potential of combining CRT with angiostatic agents, some further background on the complex interaction between RT and the vascular system is helpful. A classic study demonstrated that radiation effects on endothelial cells and, thus, on angiogenesis are dose dependent. 128 Whereas increased tumor vascularization and blood flow was observed after a single treatment of 2Y3 Gy, treatment with 6 Gy caused a decrease in tumor vasculature and blood flow, suggesting that low-dose irradiation might directly potentiate tumor angiogenesis. 128 Recent studies in several different preclinical systems have supported the differential effects of low and high doses of radiation on the vascular system. 129 Although angiostatic drugs might inhibit the induction of angiogenesis by RT, the disruption of the tumor vasculature by such agents would hinder proper perfusion of the tumor. Because hypoxic regions are resistant to RT, the combination of angiostatic therapy with RT seems paradoxical. However, several preclinical studies found a positive interaction between angiogenesis inhibition and RT. 130 Interestingly angiostatic therapy actually increased tumor oxygenation in some cases. 130 The concept of vascular normalization attempts to reconcile this paradox. 131 Vascular normalization involves the remodeling of a dysfunctional (tumor) vasculature to a more normal phenotype. It occurs when the angiostatic agents restore the balance between antiangiogenesis and proangiogenesis factors in the tumor microenvironment. Few clinical studies have addressed the use of angiostatic agents in combination with CRT. 132 Despite the activity of bevacizumab combined with chemotherapy in advanced NSCLC, 125 strategies to combine this angiostatic agent with RT have proved disappointing because of toxicity. Phase II trials in NSCLC and in limited stage small-cell lung cancer were abandoned because of higher than anticipated tracheoesophageal fistulation and pulmonary hemorrhage. A phase I study to determine the safety of two dose levels of bevacizumab with RT alone has also been halted because of toxicity concerns. The approach of combining VEGF and EGFR inhibitors was tested using concurrent bevacizumab, erlotinib, carboplatin, paxlitaxel, and RT, but consolidation therapy with bevacizumab/erlotinib was determined not to be feasible. The squamous histology cohort was closed because of pulmonary hemorrhage. Median overall survival was 19 months (non-squamous = 19 months vs. squamous = 17 months), which was similar to the results of concurrent chemoradiotherapy alone. The multitargeted antiangiogenic TKI sunitinib is currently being tested in phase I and phase II studies.
SUMMARY
We have summarized two radiation-inducible inflammation pathways, the inhibition of which increases the radioresponse of cells in culture and animal tumor models. Progress with the eicosanoid pathway has been hampered by the side effects of COX-2 inhibitors. Recently, there has been a focus on inhibiting microsomal PGE synthase-1, the terminal synthase responsible for the synthesis of the protumorigenic PGE-2. mPGES-1is overexpressed in a wide variety of cancers and the effects of a variety of new specific inhibitors of this enzyme are subject to ongoing studies. 133 It has been well established that increased expression of cPLA 2 and ATX in cancer cells and tumor microenvironment play a role in tumor progression, metastasis, migration, and proliferation. Activation of cPLA 2 by ionizing radiation leads to increased survival and viability of vascular endothelial cells 16 and could contribute to poor outcomes in RT and CRT. Recent data using inhibitors of cPLA 2 49,50,55 and inhibitors of ATX and LPA receptors 48 show a great promise for the validation of cytosolic phospholipase A 2 autotaxin and lysophosphatidic acid receptors as molecular targets for the development of novel radiosensitizers, for the improvement of lung cancer 61 and malignant glioma 48 treatment. The EML4-ALK fusion gene appears unique to NSCLC. In a remarkably short period of time, from its initial discovery to clinical validation, ALK-targeted therapies are in advanced clinical development for EML4-ALK NSCLC. 134 EML4-ALK NSCLC represents a unique subset of NSCLC patients for whom ALK inhibitors may represent a very effective therapeutic strategy. Some recent efforts to circumvent ALK inhibitor resistance have involved novel inhibitors designed to inhibit Hsp90. 116 There has been a considerable effort to determine the effect of Hsp90 inhibitors in lung cancer, mainly focusing on the naturally occurring antibiotic Geldanamycin and its derivatives. 135 The prospect of developing combinatorial approaches using TKI and Hsp90 inhibitors and overcoming resistance to TKI with Hsp90 inhibitors are exciting new advances in NSCLC treatment.
